Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
34
NBTX Quote, Financials, Valuation and Earnings
Last price:
$2.96
Seasonality move
:
-8.02%
Day range:
$2.93 - $3.19
52-week range:
$2.76 - $8.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.29x
P/B ratio:
--
Volume:
49.5K
Avg. volume:
53.1K
1-year change:
-60.92%
Market cap:
$141.7M
Revenue:
$32.5M
EPS (TTM):
-$0.80
Analysts' Opinion
-
Consensus RatingNanobiotix SA has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.47, Nanobiotix SA has an estimated upside of 244.96% from its current price of $2.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $2.99.
Fair Value
-
According to the consensus of 3 analysts, Nanobiotix SA has 244.96% upside to fair value with a price target of $10.47 per share.
NBTX vs. S&P 500
-
Over the past 5 trading days, Nanobiotix SA has underperformed the S&P 500 by -1.9% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nanobiotix SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nanobiotix SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Nanobiotix SA reported revenues of --.
Earnings Growth
-
Nanobiotix SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nanobiotix SA reported earnings per share of --.
Enterprise value:
118.3M
EV / Invested capital:
--
Price / LTM sales:
3.29x
EV / EBIT:
--
EV / Revenue:
3.03x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-71.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-44.94%
Net Income Margin (TTM):
-92.41%
Return On Equity:
--
Return On Invested Capital:
-161.14%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-08 | 2024-01-08 | 2024-01-08 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $39.7M | $137.9M | $76.1M | $36.5M | $86.2M | |
| Total Assets | $50.3M | $147.5M | $84.2M | $43.9M | $92.9M | |
| Current Liabilities | $19.3M | $45.3M | $44.5M | $54.2M | $60.6M | |
| Total Liabilities | $75.3M | $98.2M | $82.3M | $102.4M | $116.3M | |
| Total Equity | -$25M | $49.3M | $1.9M | -$58.4M | -$23.3M | |
| Total Debt | $50.9M | $53.7M | $40.9M | $53M | $47.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-08 | 2024-01-08 | 2024-01-08 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
NBTX
Sector
Market Cap
$141.7M
$48.9M
Price % of 52-Week High
33.36%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-60.92%
-30.56%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.96
200-day SMA
Sell
Level
$5.10
Bollinger Bands (100)
Sell
Level
3.49 - 5.25
Chaikin Money Flow
Buy
Level
5.2M
20-day SMA
Sell
Level
$3.15
Relative Strength Index (RSI14)
Sell
Level
39.73
ADX Line
Sell
Level
21.63
Williams %R
Buy
Level
-85.3659
50-day SMA
Sell
Level
$3.61
MACD (12, 26)
Sell
Level
-0.19
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
47.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.0572)
Sell
CA Score
(Annual)
Level (-5.295)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.3354)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Stock Forecast FAQ
In the current month, NBTX has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NBTX average analyst price target in the past 3 months is $10.47.
-
Where Will Nanobiotix SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nanobiotix SA share price will rise to $10.47 per share over the next 12 months.
-
What Do Analysts Say About Nanobiotix SA?
Analysts are divided on their view about Nanobiotix SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nanobiotix SA is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Nanobiotix SA's Price Target?
The price target for Nanobiotix SA over the next 1-year time period is forecast to be $10.47 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NBTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nanobiotix SA is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NBTX?
You can purchase shares of Nanobiotix SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nanobiotix SA shares.
-
What Is The Nanobiotix SA Share Price Today?
Nanobiotix SA was last trading at $2.96 per share. This represents the most recent stock quote for Nanobiotix SA. Yesterday, Nanobiotix SA closed at $2.99 per share.
-
How To Buy Nanobiotix SA Stock Online?
In order to purchase Nanobiotix SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
